Lifting the California mask mandate basically says chronically ill and disabled lives don’t matter
By Dipti S. Barot,
San Francisco Chronicle
| 02. 16. 2022
Photo by Kai Pilger on Unsplash
As the omicron surge wanes, and the experts read the sewage like tea leaves, states from New York to California and everywhere in between have rushed to remove mask mandates, declaring that we have reached the magic inflection point between pandemic and endemic. And, once again, it will be the medically vulnerable who will suffer the casualties in this premature push for normalcy while COVID deaths in the U.S. still average near 2,500 per day.
One can’t help but recall the disastrous Centers for Disease Control and Prevention decision to recommend removing mask mandates in May 2021 and the subsequent walk back a mere two months later due to the delta variant. Even as we learn about long COVID and its disastrous effects, why do these policies reflect a greater concern for the robustness of the economy than the robustness of its citizens?
For me, an immunocompromised physician, the true kickoff to the pandemic was two Februaries ago when a colleague persisted in flouting our clinic’s coronavirus distancing guidelines by approaching too close and...
Related Articles
By Jacob M. Apel, The Baltimore Sun | 08.16.2024
By Neha Kondaveeti, The Austin Chronicle | 08.16.2024
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...